<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadlines</th>
</tr>
</thead>
</table>
| **Clinical Translational Research Award**           | Must be an independent investigator at or above the level of Assistant Professor (or equivalent). | • Supports translational research addressing high-impact or unmet needs in ovarian cancer.  
• Supports correlative studies related to or associated with planned, ongoing, or completed clinical trials supported by other funding sources.  
• Emphasis on the utilization of precision medicine and computational approaches that identify individual tumor characteristics and predictive biomarkers across diverse groups to optimize patient care and outcomes.  
• Preliminary data are required.  
• Clinical trials are not allowed.  
• Pre-application is required; application is by invitation only.                                                                 | • Maximum funding of $450,000 for direct costs (plus indirect costs).  
• Maximum period of performance is 3 years.                                                                                                                                                                                                                                                                                                                                 | Pre-Application:  
April 01, 2021  
5:00 p.m. Eastern Time (ET)  
Application:  
July 08, 2021  
11:59 p.m. ET                                                                                                                                                                                                                                           |
| **Investigator-Initiated Research Award**           | Must be an independent investigator at or above the level of Assistant Professor (or equivalent). | • Supports meritorious basic and clinically oriented research in ovarian cancer.  
• Impact is an important review criterion.  
• Preliminary data are required.  
• Clinical trials are not allowed.  
• Pre-application is required; application is by invitation only.                                                                 | • Maximum funding of $600,000 for direct costs (plus indirect costs).  
• Maximum funding of $800,000 for direct costs (plus indirect costs) for Partnering PI Option.  
• Maximum period of performance is 4 years.                                                                                                                                                                                                                                                                 | Pre-Application:  
April 01, 2021  
5:00 p.m. ET  
Application:  
July 08, 2021  
11:59 p.m. ET                                                                                                                                                                                                                                           |
<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadlines</th>
</tr>
</thead>
</table>
| **Ovarian Cancer Academy Award – Early-Career Investigator** | Must be within 5 years of his/her last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.) or equivalent as of the full application submission deadline. A Statement of Eligibility is required. | • Supports the addition of new Early-Career Investigators to the unique, interactive virtual academy providing intensive mentoring, national networking, and a peer group for junior faculty.  
  • Early-Career Investigators whose ability to commit to conducting ovarian cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.  
  • A Designated Mentor who is an experienced ovarian cancer researcher with ovarian cancer funding is required.  
  • A Designated Mentor may only mentor one Early-Career Investigator.  
  • The Designated Mentor is not required to be at the same institution as the Early-Career Investigator.  
  • Preliminary data are required.  
  • Clinical trials are allowed.  
  • **Pre-application is required; application is by invitation only.** | • Maximum funding of **$725,000** for direct costs (plus indirect costs).  
  • Maximum period of performance is 4 years. | **Pre-Application:**  
  April 01, 2021  
  5:00 p.m. ET  
  **Application:**  
  July 08, 2021  
  11:59 p.m. ET |
| **Pilot Award**                        |Investigators at or above the postdoctoral level (or equivalent).            | • Supports innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancements that will drive the field of ovarian cancer research forward.  
  • Innovation and Impact are important review criteria.  
  • Goal is to develop preliminary data; thus, preliminary data are not required, but are allowed.  
  • Clinical trials are not allowed.  
  • **Pre-application is required and is blinded; application is by invitation only.** | • Maximum funding of **$250,000** for direct costs (plus indirect costs).  
  • Maximum period of performance is 2 years. | **Pre-Application:**  
  April 01, 2021  
  5:00 p.m. ET  
  **Application:**  
  July 08, 2021  
  11:59 p.m. ET |
<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadlines</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proteogenomics Research Award</td>
<td>Must be at or above the level of postdoctoral fellow (or equivalent).</td>
<td>• Supports the genomic and/or transcriptomic and/or proteomic analysis of currently available clinical specimens with a focus on answering biologic and pathophysiologic questions of clinical relevance in ovarian cancer.</td>
<td>• Maximum funding of $250,000 for direct costs (plus indirect costs).</td>
<td>Pre-Application: April 01, 2021 5:00 p.m. ET</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Innovation and impact are important review criteria.</td>
<td>• Maximum period of performance is 2 years.</td>
<td>Application: July 08, 2021 11:59 p.m. ET</td>
</tr>
<tr>
<td>Grants.gov Funding Opportunity Number: W81XWH-21-OCRP-PGRA</td>
<td></td>
<td>• Analysis of clinical trial-derived specimens and/or large patient specimen cohorts is encouraged.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Clinical trials are not allowed.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Preliminary data are not required but are allowed.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Pre-application is required; application is by invitation only.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Award Mechanism</td>
<td>Eligibility</td>
<td>Key Mechanism Elements</td>
<td>Funding</td>
<td>Submission Deadlines</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------</td>
<td>-------------------------------------------</td>
</tr>
</tbody>
</table>
| Omics Consortium Award          | Must be an independent investigator at or above the level of Assistant Professor (or equivalent). | • Supports a multi-institutional research effort conducted by leading cancer researchers and advocates that focuses on the compilation of new and/or use of existing large datasets to study the origin of ovarian cancer, with an emphasis on early detection and screening.  
  Two options are available:  
  **Omics Development Award Option:**  
  • Funds support assembling consortium members and laying the groundwork for the research project, including proof of concept.  
  • Ovarian cancer advocate(s) are required on the research team.  
  • Funded applicants will be eligible to compete for the consortium award, which will support the execution of the full research project and is anticipated to be offered in FY23, pending availability of funds.  
  **Omics Consortium Award Option:**  
  • The research effort will provide immediate benefits for ovarian cancer patients in initial diagnosis and therapy and the end result will lead to improvements in early detection and screening detection of ovarian cancer.  
  • Consortium should maximize the use of resources and minimize unnecessary duplication among consortium members by sharing resources among all consortium members.  
  • Ovarian cancer advocate(s) are required on the research team.  
  • **Submission of a Letter of Intent is required prior to full application submission.** | **Omics Development Award Option:**  
  • Maximum funding of $**400,000** for direct costs (plus indirect costs).  
  • Maximum period of performance is 2 years.  
  **Omics Consortium Award Option:**  
  • Maximum funding of **$2.5 million** for direct costs (plus indirect costs) from FY21 and future appropriations.  
  • Maximum period of performance is 4 years. | Pre-Application:  
  June 24, 2021  
  5:00 p.m. ET  
  Application:  
  July 08, 2021  
  11:59 p.m. ET |

Grants.gov Funding Opportunity Number: W81XWH-21-OCR-POMCA